|
| Press Releases |
|
 |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
| Friday, February 14, 2020 |
|
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
| Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Aleen Inc. Introduces Biomarker Data Layer in Personal Wellness Account
Mar 25, 2026 23:28 HKT/SGT
|
|
|
Hengrui Pharma Announces Strong 2025 Annual Results
Mar 25, 2026 23:15 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB49.9 Million in 2025
Mar 25, 2026 22:39 HKT/SGT
|
|
|
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
Mar 25, 2026 20:30 HKT/SGT
|
|
|
Adyton Reports 6.60g/t Au, 2.44% Cu and 39.8g/t Ag Within 164m @ 0.82g/t AuEq Including 53m at 1.60g/t AuEq Within 164m at 0.82g/t AuEq from the Northeastern Extension Target, Feni Island
Mar 25, 2026 19:29 HKT/SGT
|
|
|
Emperor Watch & Jewellery Limited Announces 2025 Annual Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
Kingsoft announces 2025 Annual and Fourth Quarter Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
New 2026 Office Bearers Announced for CropLife Asia
Mar 25, 2026 18:00 HKT/SGT
|
|
|
IGG 'Doomsday: Last Survivors' Achieves Record-High Monthly Gross Billing of HK$130 Million
Mar 25, 2026 17:40 HKT/SGT
|
|
|
Exito Media Concepts Announces the 31st Global Edition of the Cyber Security Summit Australia 2026 
Mar 25, 2026 17:18 HKT/SGT
|
|
|
Exito Media Concepts Announces the 33rd Global Edition of the BFSI IT Summit Australia 2026
Mar 25, 2026 16:58 HKT/SGT
|
|
|
GTJAI (1788.HK) Achieved Record-High Revenue in 2025 with Profitability Making a Leapfrog Improvement
Mar 25, 2026 16:44 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 25, 2026 16:34 HKT/SGT
|
|
|
Thailand Exhibition Association Unveils Transformative MICE Masterplan 2026-2027
Mar 25, 2026 16:26 HKT/SGT
|
|
|
Sumitomo Heavy Industries and NEC to develop system capable of identifying and reporting near-miss incidents
Mar 25, 2026 14:27 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
